# Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

> **NCT05987956** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair** · enrollment: 600 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Alectinib - Usual
- **DRUG:** Alectinib - Study

## Key facts

- **NCT ID:** NCT05987956
- **Lead sponsor:** Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2026-11-18
- **Final completion:** 2026-12-28
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05987956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05987956, "Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05987956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*